6 pending office actions • 2 clients
| Client (Assignee) | Pending OAs |
|---|---|
| Lantern Pharma Inc. | 4 |
| Lantern Pharma Inc. | 2 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18424930 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. | KUCHARCZK, JED A | 1623 | Non-Final OA | Jan 29, 2024 |
| 18238512 | ILLUDIN ANALOGS, USES THEREOF, AND METHODS FOR SYNTHESIZING THE SAME | Lantern Pharma Inc. | BONAPARTE, AMY C | 1692 | Non-Final OA | Aug 27, 2023 |
| 18349256 | TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENE | Lantern Pharma Inc. | BRAUN, MADELINE E | 1624 | Non-Final OA | Jul 10, 2023 |
| 17998117 | Method For Treating Pancreatic Cancer | Lantern Pharma Inc. | MAHLUM, JONATHAN DAVIS | 1625 | Non-Final OA | Nov 07, 2022 |
| 17995904 | Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer | Lantern Pharma Inc. | WILSON, JERICA KATLYNN | 1621 | Final Rejection | Oct 10, 2022 |
| 17230821 | Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers | Lantern Pharma Inc. | VISONE, THOMAS J | 1672 | Final Rejection | Apr 14, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial